RT Journal Article
T1 Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.
A1 Salvadó, Gemma
A1 Grothe, Michel J
A1 Groot, Colin
A1 Moscoso, Alexis
A1 Schöll, Michael
A1 Gispert, Juan Domingo
A1 Ossenkoppele, Rik
A1 Alzheimer’s Disease Neuroimaging Initiative, 
K1 APOE
K1 Amyloid-β
K1 Cognition
K1 Cross-sectional
K1 Hippocampal volumes
K1 Longitudinal
K1 PET
K1 Sex interaction
K1 Tau
AB To examine associations between the APOE-ε2 and APOE-ε4 alleles and core Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia. We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([18F]florbetapir or [18F]florbetaben) and tau ([18F]flortaucipir) PET, structural MRI, and cognitive testing. Employing APOE-ε3 homozygotes as the reference group, associations between APOE-ε2 and APOE-ε4 carriership with global Aβ PET and regional tau PET measures (entorhinal cortex (ERC), inferior temporal cortex, and Braak-V/VI neocortical composite regions) were investigated using linear regression models. In a subset of 156 participants, we also investigated associations between APOE genotype and regional tau accumulation over time using linear mixed models. Finally, we assessed whether Aβ mediated the cross-sectional and longitudinal associations between APOE genotype and tau. Compared to APOE-ε3 homozygotes, APOE-ε2 carriers had lower global Aβ burden (βstd [95% confidence interval (CI)]: - 0.31 [- 0.45, - 0.16], p = 0.034) but did not differ on regional tau burden or tau accumulation over time. APOE-ε4 participants showed higher Aβ (βstd [95%CI]: 0.64 [0.42, 0.82], p  Our data suggest that the established protective effect of the APOE-ε2 allele against developing clinical AD is primarily linked to resistance against Aβ deposition rather than tau pathology.
YR 2021
FD 2021-02-01
LK http://hdl.handle.net/10668/17078
UL http://hdl.handle.net/10668/17078
LA en
DS RISalud
RD Apr 6, 2025